Gilead Sciences Inc

GILD34.SA ยท Healthcare ยท Drug Manufacturers - General ยท BRL ยท Fundamentals
Asset-light

Physical assets are 16.9% of total assets, a light footprint. Capex is 0.20x depreciation while free cash flow yield is positive, which can mean an aging base that is still throwing off cash. ROIC is 23.6%, above an 8% cost-of-capital hurdle.

Fixed-asset turnover is 5.25x. Compare it with other names in the same basket.

Physical asset ratio
16.9%
Net PP&E plus inventory, divided by total assets. Above 50% is a heavy footprint.
Fixed asset turnover
5.25x
Revenue per dollar of the physical asset base.
Capex / D&A
0.20x
Above 1.0x means the physical base is being replaced or expanded.
Tangible book / share
-BRL 2.15
Assets minus goodwill, intangibles, and liabilities, per share.
Price / tangible book
โ€”
Price BRL 65.81.
Fixed-charge coverage
12.71x
EBITDA minus capex, divided by interest plus short-term debt.
FCF yield
1.0%
Latest free cash flow divided by current market cap (BRL 979.22B).
ROIC
23.6%
After-tax operating income over equity plus debt minus cash. Operating income / net PP&E is 1.79x.

Footprint and return

Turnover and reinvestment

Year Physical FAT Capex/D&A TBV/sh Coverage FCF ROIC EBIT/PP&E
2018 7.6% 5.52x 0.65x BRL 1.20 2.45x BRL 7.48B 30.8% 2.05x
2019 9.9% 4.34x 0.59x BRL 3.65 1.93x BRL 8.32B 18.8% 0.83x
2020 10.7% 4.40x 0.44x -BRL 18.37 3.54x BRL 7.52B 6.2% 0.73x
2021 10.7% 4.82x 0.28x -BRL 16.53 8.69x BRL 10.81B 18.9% 1.78x
2022 11.9% 4.56x 0.35x -BRL 12.81 6.44x BRL 8.34B 14.4% 1.23x
2023 11.4% 5.10x 0.20x -BRL 9.65 10.53x BRL 7.85B 15.3% 1.43x
2024 12.1% 5.31x 0.19x -BRL 7.23 4.00x BRL 10.31B 3.2% 0.31x
2025 16.9% 5.25x 0.20x -BRL 2.15 12.71x BRL 9.46B 23.6% 1.79x
  • Principal due is short-term debt, the amount reported as due within a year.
Latest year inputs (2025)
Net PP&E: BRL 5.61B
Inventory: BRL 4.37B
Total assets: BRL 59.02B
Goodwill: BRL 8.31B
Intangibles: BRL 16.98B
Liabilities: BRL 36.41B
Tangible book: -BRL 2.67B
Shares: 1,241,000,000
Revenue: BRL 29.44B
Capex: BRL 563.00M
D&A: BRL 2.76B
EBITDA: BRL 13.58B
Interest: BRL 1.02B
Short-term debt: BRL 0.00
Free cash flow: BRL 9.46B
Operating income: BRL 10.02B
Invested capital: BRL 36.95B
Tax rate: 13.1%